HomeIPN • EPA
add
Ipsen SA
Previous close
€115.10
Day range
€113.90 - €115.80
Year range
€99.70 - €130.70
Market cap
9.75B EUR
Avg Volume
69.24K
P/E ratio
15.47
Dividend yield
1.05%
Primary exchange
EPA
Market news
.INX
1.26%
1.00%
Financials
Income Statement
Revenue
Net income
(EUR) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | — | — |
Net income | — | — |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(EUR) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 528.40M | -54.81% |
Total assets | 6.32B | 12.62% |
Total liabilities | 2.50B | 10.03% |
Total equity | 3.82B | — |
Shares outstanding | 82.72M | — |
Price to book | 2.49 | — |
Return on assets | — | — |
Return on capital | — | — |
Cash Flow
Net change in cash
(EUR) | Dec 2023info | Y/Y change |
---|---|---|
Net income | — | — |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
CEO
Founded
1929
Website
Employees
5,325